• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

VINCRISTINE Drug Record

  • Summary
  • Interactions
  • Claims
  • VINCRISTINE chembl:CHEMBL90555 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    VINCRISTINE
    LEUROCRISTINE
    NSC-67574
    LEUROCRISTINE SULFATE
    VINCRISTIN
    ONCOVIN®
    22-OXOVINCALEUKOBLASTINE
    VINCRISTINUM
    KYOCRISTINE
    22-OXOVINCALEUKOBLASTIN
    VINCRISTINA
    pubchem.compound:5978
    chemidplus:57-22-7
    rxcui:11202
    chembl:CHEMBL90555
    drugbank:00541

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    Year of Approval 1963
    Drug Class antineoplastic agents
    (6 More Sources)

    Publications:

    Kalra S et al., 2018, Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
    Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia
    Wick et al., 2004, Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity., J. Neurochem.
    Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem
    Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett
    Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem
    Gutierrez-Camino A et al., 2017, PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort., Clin Pharmacol Ther
    López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
    Vellon et al., 2007, Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner., Differentiation
    Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA
    Kurtzberg et al., 2009, Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents., Cancer Chemother. Pharmacol.
    Gan et al., 2010, Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin., Mol. Cancer Ther.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
    Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
    Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.
    Yasui et al., 2010, Live cell imaging of micronucleus formation and development., Mutat. Res.
    Vilpo et al., 2000, Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro., Eur. J. Haematol.
    Sano, 2001, Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons., Neuropharmacology
    Kobrinsky et al., 2005, Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue., Pediatr Blood Cancer
    Pui et al., 1985, Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia., J. Clin. Oncol.
    Schinkel et al., 1991, Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies., Cancer Res.
    Ahn et al., 1997, Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin., J. Nat. Prod.
    Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
    Jordheim LP et al., 2015, Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma., Haematologica
    Gregers J et al., 2015, Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia., Pharmacogenomics J
    Maggini V et al., 2008, MDR1 diplotypes as prognostic markers in multiple myeloma., Pharmacogenet Genomics
    Lopez-Lopez E et al., 2016, Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia., Pharmacogenomics
    Filipits et al., 2003, Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma., Clin. Cancer Res.
    Andreani A et al., 2008, Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events., J Med Chem
    Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.
    Klauber et al., 1997, Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol., Cancer Res.
    McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.
    Fujiwara et al., 2007, Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated., Mol. Cancer Ther.
    Shingu et al., 2003, Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells., Cancer Res.
    Tsukamoto et al., 1989, Effect of colchicine and vincristine on DNA synthesis in regenerating rat liver., Biochim. Biophys. Acta
    Twentyman et al., 1990, Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin)., Br. J. Cancer
    Moriyama T et al., 2015, Inherited genetic variation in childhood acute lymphoblastic leukemia., Blood
  • VINCRISTINE   CEP72

    Interaction Score: 2.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25999454


    Sources:
    PharmGKB

  • VINCRISTINE   RALBP1

    Interaction Score: 1.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27180762


    Sources:
    PharmGKB

  • VINCRISTINE   ACTG1

    Interaction Score: 1.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VINCRISTINE   CAPG

    Interaction Score: 1.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VINCRISTINE   ODC1

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19006285


    Sources:
    DTC

  • VINCRISTINE   SRI

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1975203


    Sources:
    NCI

  • VINCRISTINE   PNPLA3

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28744905


    Sources:
    PharmGKB

  • VINCRISTINE   GSTA1

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 19448608


    Sources:
    PharmGKB

  • VINCRISTINE   ABCB4

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1673638


    Sources:
    NCI

  • VINCRISTINE   CXCL12

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27173875


    Sources:
    PharmGKB

  • VINCRISTINE   DROSHA

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24614921


    Sources:
    PharmGKB

  • VINCRISTINE   ABCC10

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VINCRISTINE   MYCN

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12439032


    Sources:
    NCI

  • VINCRISTINE   ATRX

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23904111


    Sources:
    CIViC

  • VINCRISTINE   BMP7

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • VINCRISTINE   LINC00251

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • VINCRISTINE   DOK5

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • VINCRISTINE   TUBA4A

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo
    Novel drug target Established target

    PMIDs:
    20442307 20691709 11168494 21664138 23916255 16539377


    Sources:
    DTC TdgClinicalTrial

  • VINCRISTINE   TUBB4A

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   TUBA3C

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   TUBB

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    19277662 20442307 17016423 17139284 21664138 23916255 16539377


    Sources:
    DTC TTD

  • VINCRISTINE   CDKN1B

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12576455


    Sources:
    NCI

  • VINCRISTINE   AFP

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15770640


    Sources:
    NCI

  • VINCRISTINE   BCR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Fusion protein BCR:ABL1

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • VINCRISTINE   GATA3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24141364


    Sources:
    PharmGKB

  • VINCRISTINE   TUBB2A

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo
    Novel drug target Established target

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC TdgClinicalTrial TEND

  • VINCRISTINE   CP

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9392881


    Sources:
    NCI

  • VINCRISTINE   VWF

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3875694


    Sources:
    NCI

  • VINCRISTINE   NTF3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11378165


    Sources:
    NCI

  • VINCRISTINE   TUBB6

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16539377 21664138 23916255


    Sources:
    DTC

  • VINCRISTINE   TUBA1B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   TUBA3D

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   TUBA1C

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   TUBA3E

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   TUBB8

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   TUBB2B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   TUBA1A

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   TUBB3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   FGF2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8988045


    Sources:
    NCI

  • VINCRISTINE   TUBB4B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   NRG1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17999741


    Sources:
    NCI

  • VINCRISTINE   ABCC3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22016816


    Sources:
    PharmGKB

  • VINCRISTINE   TUBB1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21664138 23916255 16539377


    Sources:
    DTC

  • VINCRISTINE   TYMS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2804079


    Sources:
    NCI

  • VINCRISTINE   PIK3CG

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17363506 12874004


    Sources:
    NCI

  • VINCRISTINE   BDNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15569250


    Sources:
    NCI

  • VINCRISTINE   ABL1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Fusion protein BCR:ABL1

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • VINCRISTINE   TOP2A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9494516


    Sources:
    NCI

  • VINCRISTINE   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 25637052 25582575 22016816 18408561


    Sources:
    PharmGKB

  • VINCRISTINE   BCL2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VINCRISTINE   ABCC1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VINCRISTINE   ABCC2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VINCRISTINE   PIK3CA

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12874004


    Sources:
    NCI

  • VINCRISTINE   CYP3A5

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VINCRISTINE   NR1I2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VINCRISTINE   SMAD3

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VINCRISTINE   GMNN

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VINCRISTINE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: VINCRISTINE

    • Version: 01-August-2011

    Alternate Names:
    VINCRISTINE Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 1963

    Publications:

  • TdgClinicalTrial: VINCRISTINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: VINCRISTINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL90555 ChEMBL Drug ID

    Drug Info:

    Publications:
    Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem
    Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem
    Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

  • NCI: VINCRISTINE

    • Version: 14-September-2017

    Alternate Names:
    C933 NCI drug code

    Drug Info:

    Publications:
    Tsukamoto et al., 1989, Effect of colchicine and vincristine on DNA synthesis in regenerating rat liver., Biochim. Biophys. Acta
    Ahn et al., 1997, Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin., J. Nat. Prod.
    Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.

  • PharmGKB: vincristine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Kalra S et al., 2018, Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
    Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia
    Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

  • CIViC: VINCRISTINE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.

  • TTD: Vincristine

    • Version: 2020.06.01

    Alternate Names:
    D09QVV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL90555

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Vincristine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: VINCRISTINE

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21